Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
2.
Front Microbiol ; 13: 1000787, 2022.
Article in English | MEDLINE | ID: mdl-36246266

ABSTRACT

Objectives: Little is known about IMP-producing Enterobacterales (IMP-Ent) in Europe. We analyzed at genomic and phenotypic level IMP-Ent isolates circulating in Spain in a 9-year period. Materials and methods: IMP-Ent isolates submitted to our reference laboratory were included. Antibiotic susceptibility was performed using microdilution method (EUCAST), and IMP-carbapenemase activity was measured with carbapenemase inhibitors, the ß-CARBA method, the modified Hodge test (MHT), and the modified carbapenemase inhibition method (mCIM). All isolates collected were sequenced for high-resolution single-nucleotide polymorphism (SNP) typing, core genome multilocus sequence typing (cgMLST), and resistome analysis. Results: Fifty IMP-Ent isolates, collected from 19 hospitals in 13 Spanish provinces, were detected: Klebsiella pneumoniae (IMP-Kpn) (24; 48%), Enterobacter roggenkampii (13; 26%), Enterobacter hormaechei (8, 16%), Klebsiella oxytoca (two; 4%), Enterobacter asburiae (one, 2%), Serratia marcescens (one; 2%) and Escherichia coli (one; 2%). All isolates were positive by the MHT and ß-CARBA tests; 48 (96%) were mCIM positive; 12 (24%) and 26 (52%) displayed positive inhibition with dipicolinic (meropenem) and EDTA (ertapenem), respectively. Five IMP-carbapenemase types were identified: IMP-8 (22; 44%), IMP-22 (17; 34%), IMP-13 (7; 14%), IMP-28 (two; 4%), and IMP-15 (two; 4%), predominating IMP-8 in K. pneumoniae and IMP-22 in E. roggenkampii. IMP-28 was exclusively identified in K. oxytoca and IMP-15 in E. hormaechei. Predominant STs were ST405 (29.2%), ST15 (25%) and ST464 (20.8%) in IMP-Kpn; ST96 (100%) in E. roggenkampii and ST182 (62.5%) in E. hormachei. Colistin and amikacin were the most active non-carbapenem antibiotics against IMP-Ent. Conclusion: IMP-Ent isolates remain infrequent in Spain, although in recent years have been circulating causing nosocomial outbreaks, being IMP-8-producing K. pneumoniae and IMP-22-producing E. roggenkampii the most frequently detected in this study. Inhibition with EDTA or dipicolinic acid presented false negative results in some IMP-producing strains. Active microbiological and molecular surveillance is essential for a better comprehension and control of IMP-Ent dissemination.

3.
Virulence ; 12(1): 2919-2931, 2021 12.
Article in English | MEDLINE | ID: mdl-34874239

ABSTRACT

Antiretroviral therapy (ART) allows suppressed viremia to reach less than 50 copies/mL in most treated persons living with HIV (PLWH). However, the existence of PLWH that show events of persistent low-level viremia (pLLV) between 50 and 1000 copies/mL and with different virological consequences have been observed. PLLV has been associated with higher virological failure (VF), viral genotype resistance, adherence difficulties and AIDS events. Moreover, some reports show that pLLV status can lead to residual immune activation and inflammation, with an increased risk of immunovirological failure and a pro-inflammatory cytokine level which can lead to a higher occurrence of non-AIDS defining events (NADEs) and other adverse clinical outcomes. Until now, however, published data have shown controversial results that hinder understanding of the true cause(s) and origin(s) of this phenomenon. Molecular mechanisms related to viral reservoir size and clonal expansion have been suggested as the possible origin of pLLV. This review aims to assess recent findings to provide a global view of the role of pLLV in PLWH and the impact this status may cause on the clinical progression of these patients.


Subject(s)
HIV Infections , Viremia , Antiretroviral Therapy, Highly Active , Genotype , HIV Infections/drug therapy , Humans , Viral Load , Viremia/drug therapy
4.
Emerg Infect Dis ; 28(2): 394-402, 2021 02.
Article in English | MEDLINE | ID: mdl-35076008

ABSTRACT

Human cases of Crimean-Congo hemorrhagic fever (CCHF) were first detected in Spain in 2016. National human and animal health authorities organized a large, multidisciplinary study focusing on ticks as sentinels to determine the nationwide distribution of ticks with CCHF virus. Ticks were collected from animals and vegetation, samples pooled (12,584 ticks; 4,556 pools), and molecular methods used to look for the virus. We detected the virus in 135 pools from most of the regions studied, indicating that it is widespread in Spain. We found sequences of CCHF virus genotypes I, III, and IV in the tick species collected, most commonly in Hyalomma lusitanicum, suggesting this tick has a prominent role in the virus's natural cycle. The red deer (Cervus elaphus) was the host that most frequently yielded positive ticks. Our study highlights the need for larger studies in Spain to ascertain the complete risk to public health.


Subject(s)
Deer , Hemorrhagic Fever Virus, Crimean-Congo , Hemorrhagic Fever, Crimean , Ticks , Animals , Hemorrhagic Fever Virus, Crimean-Congo/genetics , Hemorrhagic Fever, Crimean/diagnosis , Spain/epidemiology
5.
Virology ; 492: 53-65, 2016 May.
Article in English | MEDLINE | ID: mdl-26896935

ABSTRACT

West Nile virus (WNV) is the most widespread arbovirus in the world. Several recent outbreaks and epizootics have been reported in Europe and the Mediterranean basin with increased virulence. In contrast to the well-characterized American and Australian strains, little is known about the virulence determinants of the WNV European-Mediterranean strains. To investigate the viral factors involved in the virulence of these strains, we generated chimeras between the highly neuropathogenic Israel 1998 (IS-98-ST1, IS98) strain and the non-pathogenic Malaysian Kunjin virus (KJMP-502). In vivo analyses in a mouse model of WNV pathogenesis shows that chimeric virus where KJMP-502 E glycoprotein was replaced by that of IS98 is neuropathogenic, demonstrating that this protein is a major virulence determinant. Presence of the N-glycosylation site had limited impact on virus virulence and the 5'UTR does not seem to influence pathogenesis. Finally, mice inoculated with KJMP-502 virus were protected against lethal IS98 infection.


Subject(s)
Reassortant Viruses/genetics , Viral Envelope Proteins/genetics , Viral Vaccines/administration & dosage , West Nile Fever/prevention & control , West Nile virus/pathogenicity , Animals , Disease Models, Animal , Europe/epidemiology , Female , Humans , Immunization , Mediterranean Region/epidemiology , Mice , Mice, Inbred BALB C , Protein Structure, Tertiary , Reassortant Viruses/chemistry , Reassortant Viruses/immunology , Survival Analysis , Vaccines, Attenuated , Viral Envelope Proteins/chemistry , Viral Envelope Proteins/immunology , West Nile Fever/epidemiology , West Nile Fever/immunology , West Nile Fever/mortality , West Nile virus/genetics , West Nile virus/immunology
6.
Antiviral Res ; 88(2): 152-9, 2010 Nov.
Article in English | MEDLINE | ID: mdl-20713090

ABSTRACT

Transcriptional activation of HIV-1 gene expression is partially controlled by the interaction between viral and cellular transcription factors acting at HIV-1 long terminal repeat (LTR) sequences. HIV-1 subtyping at LTR region and nucleotide LTR variability from clinical samples in 48 subjects carrying different HIV-1 subtypes (9A, 5C, 3D, 3F, 21G, 2H, 3J and 2 undefined) at the protease (PR) gene, were performed. LTR sequences from each HIV-1 clade were cloned in luciferase-expression vectors to determine basal and Tat-induced transcriptional activities in the presence and absence of PMA stimulation. A high number (37.8%) of recombinants at LTR/PR regions were identified. All HIV-1 promoters presented low basal transcriptional activity that was nevertheless induced by Tat and PMA. LTR activity was similar across the majority of HIV-1 variants in response to Tat and cell activation. Only subtype C and CRF01_AE LTRs presented higher basal and induced-PMA transcription activities than HXB2 clade B promoter. No basal or Tat/PMA induced activity was found in those promoters presenting G to A hypermutation compared to the wild type promoter activities. G to A hypermutation at some important transcription binding-factor sites within LTR compromised the activity of the viral promoter, decreasing the in vitro viral transcription of the luciferase gene.


Subject(s)
Gene Expression Regulation, Viral , HIV Infections/virology , HIV Long Terminal Repeat/genetics , HIV-1/genetics , Transcription, Genetic , tat Gene Products, Human Immunodeficiency Virus/genetics , Adult , Female , Genes, Reporter , Genes, tat , HIV Protease/genetics , HIV-1/classification , Humans , Luciferases/metabolism , Male , Middle Aged , Molecular Sequence Data , NF-kappa B/metabolism , Polymerase Chain Reaction , Promoter Regions, Genetic , Regulatory Sequences, Nucleic Acid , Sp1 Transcription Factor/metabolism , Spain , Tetradecanoylphorbol Acetate/pharmacology , Transcriptional Activation
7.
J Med Virol ; 80(3): 383-91, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18205216

ABSTRACT

Genetic recombination and high rate of mutation increase HIV-1 diversity, allowing viruses to escape more easily from the host immune response or antiretroviral drugs. The recombinant nature of full-length HIV-1 genomic sequences derived from viruses infecting five epidemiologically unlinked individuals carrying HIV-1 non-B variants was investigated. Overlapping PCR amplifications followed by direct sequencing of viral products derived from plasma and phylogenetic analyses were carried out. Four viral sequences clustered with CRF06_cpx and one with CRF02_AG. However, subtyping of separate genes within the same genome revealed that four were recombinant forms involving different subtypes and/or CRFs with distinct breakpoints. Two specimens included CRF02_AG and CRF06_cpx sequences with several fragments from other HIV-1 clades along their genomes. Three rapid subtyping tools (Stanford, NCBI, and REGA) showed discrepant results when interpreting these viral sequences. This is the first description of CRF02_AG/CRF06_ cpx recombinants in Spain. The results highlight the tremendous heterogeneity of HIV-1 recombinant strains currently in circulation.


Subject(s)
Anti-HIV Agents/therapeutic use , HIV Infections/virology , HIV-1/genetics , Recombination, Genetic , Adult , Anti-HIV Agents/pharmacology , CD4 Lymphocyte Count , Drug Resistance, Viral , Female , Genetic Variation , Genome, Viral , Genotype , HIV Infections/drug therapy , HIV-1/classification , HIV-1/drug effects , Humans , Male , Mutation , Phylogeny , Polymerase Chain Reaction/methods , Reproducibility of Results , Spain
8.
AIDS Res Hum Retroviruses ; 23(9): 1067-74, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17919099

ABSTRACT

Information about gp41 variability across distinct HIV-1 subtypes is scarce, and yet such knowledge would be desirable for designing new drugs targeting this viral protein. Conserved gp41 residues in viruses derived from 79 individuals infected with distinct HIV-1 subtypes (29 A, 25 B, 8 C, 3 D, 4 F, 4 G, 2 H, 1 J, 1 U, and 2 CRF06_cpx) and naive for entry inhibitors were examined. Conservation of gp41 was also examined in 908, 56, and 3 HIV-1 group M, O, and N sequences, respectively, available at the Los Alamos HIV Sequence Database. Among the 345 residues in the full gp41 protein, 36% showed up to 90% conservation in all 987 group M sequences, as did 40% of 56 group O sequences and 49% of 3 group N sequences. The HR1 region (residues 29-82) showed a higher proportion of highly conserved residues than did the HR2 region (residues 116-161) in all groups (65 vs. 34% in group M, 57 vs. 46% in group O, and 80 vs. 52% in group N). Some secondary resistance mutations to enfuvirtide were found as natural polymorphisms (A30V and Q56K/R in group M, Q56R and S138A in group O, and S138A in group N). In fact, A30V was a signature change in clade G and CRF06_cpx, whereas Q56K/R was a signature change for clades A and J, as well as for CRF04_cpx, CRF09_cpx, CRF11_cpx, and CRF13_cpx. The relative conservation of amino acids in gp41 across HIV-1 variants indirectly highlights the critical role of this protein for HIV infectivity and makes it feasible to design new entry inhibitors with activity against diverse HIV-1 variants.


Subject(s)
Drug Resistance, Viral/genetics , HIV Envelope Protein gp41/genetics , HIV Fusion Inhibitors/pharmacology , HIV-1/drug effects , Peptide Fragments/pharmacology , Polymorphism, Genetic , Amino Acid Sequence , Conserved Sequence , Enfuvirtide , HIV Envelope Protein gp41/chemistry , HIV Envelope Protein gp41/metabolism , HIV Envelope Protein gp41/pharmacology , HIV-1/classification , HIV-1/genetics , Humans , Molecular Sequence Data
9.
AIDS Res Hum Retroviruses ; 23(7): 891-4, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17678472

ABSTRACT

A distinct effectiveness of highly active antiretroviral therapy (HAART) in HIV-infected patients across ethnicities may reflect differences in drug adherence, host genetic factors, and/or predominant HIV subtypes. We investigated the immunologic outcome in 79 drug-naive HIV individuals living in Madrid, 39 of whom were African immigrants, who achieved and maintained undetectable viral load for up to 24 months following initiation of HAART. Overall, 90% of whites were infected with clade B viruses while 80% of Africans carried non-B subtypes. Gender, age, mean baseline viral load, and CD4 counts were comparable in both groups. The mean time to reach undetectable viremia did not differ significantly between groups. CD4 gains at 24 months following HAART initiation were also similar, although Africans showed higher CD4 gains than whites at month 12. In a multivariate analysis neither HIV subtype nor ethnicity was associated with different CD4 gains at any given time point, suggesting that reconstitution of CD4+ T cells under HAART is not influenced by ethnicity.


Subject(s)
Antiretroviral Therapy, Highly Active , CD4 Lymphocyte Count , HIV Infections/drug therapy , HIV-1/drug effects , Adult , Africa/ethnology , Female , HIV Infections/ethnology , Humans , Male , Spain , Treatment Outcome , White People
10.
AIDS Res Hum Retroviruses ; 21(11): 949-54, 2005 Nov.
Article in English | MEDLINE | ID: mdl-16386112

ABSTRACT

Transcriptional activation of HIV-1 gene expression is controlled by the interaction of sequence-specific transcription factors with the long terminal repeat (LTR). Information about differences between LTR regions in distinct HIV-1 subtypes is scarce. LTR sequences, including regulatory, enhancer, promoter, and TAR regions, were genetically characterized and compared in 59 HIV-1-infected individuals known to be infected with non-B subtypes. Phylogenetic analyses ascribed the LTR regions to the following subtypes: 10A, 2B, 6C, 1D, 2E, 2F, 16G, 3J, 2H, and 2U. Up to 34% of the samples were LTR/PR recombinants. The LTR region revealed a high degree of genetic variability among distinct HIV-1 subtypes and showed several subtype-specific markers, which hypothetically could influence the interactions with cellular transcription factors, leading to different transcriptional levels among distinct HIV-1 clades. To our knowledge, this is the first characterization of LTR sequences belonging to subtypes J and H.


Subject(s)
HIV Infections/virology , HIV Long Terminal Repeat/genetics , HIV-1/genetics , Promoter Regions, Genetic , Adult , Female , Genetic Variation , Genotype , HIV-1/isolation & purification , Humans , Male , Middle Aged , Molecular Sequence Data , Phylogeny , Polymorphism, Genetic , Recombination, Genetic , Sequence Analysis, DNA , Sequence Homology, Nucleic Acid
SELECTION OF CITATIONS
SEARCH DETAIL
...